• The Multidisciplinary Association for Psychedelic Studies (MAPS) is working to get MDMA-assisted therapy approved by the FDA for the treatment of PTSD. MAPS founder Rick Doblin believes that MDMA-assisted therapy could be legalized for prescription use as early as 2024. MDMA-assisted therapy involves administering MDMA to patients in a controlled, therapeutic setting to help them process and overcome trauma.

• The FDA has granted "breakthrough therapy" designation to MDMA-assisted therapy, which means the agency will expedite the review process. MAPS has completed Phase 3 clinical trials involving over 100 participants, and the results show that MDMA-assisted therapy is significantly more effective at treating PTSD than traditional talk therapy alone. The company is now preparing to submit its new drug application to the FDA.

• If approved, MDMA-assisted therapy could provide a new treatment option for the millions of people suffering from PTSD. Doblin believes that MDMA-assisted therapy could be a "game-changer" in the mental health field, as it has the potential to provide lasting relief from PTSD symptoms with just a few treatment sessions. The therapy is also being explored for its potential to treat other mental health conditions, such as depression and anxiety.